Immunotherapy stands at the forefront of cancer treatment, with checkpoint inhibitors like CTLA4 (cytotoxic T lymphocyte antigen-4), PD–1 (programmed death-1), and PD–L1 (programmed cell death ligand 1) demonstrating significant efficacy [139,140,141]. This evidence concerns the gene CD274 and cancer.